Phase 1 extension study of BBI503, a first-in-class cancer stemness kinase inhibitor, in patients with advanced colorectal cancer.
Year: 2015
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Derek J. Jonker, Scott Andrew Laurie, Gregory Michael Cote, Keith Flaherty, Charles S. Fuchs, Rashmi Chugh, David C. Smith, William Jeffery Edenfield, Paul R. Conkling, James Walter Mier, Rachel Anne Goodwin, Eunice Lee Kwak, Thomas Adam Abrams, Rakesh Goel, James M. Cleary, Wei Li, Youzhi Li, Jamileh Jemison, Matthew Hitron, Chiang Li
Institutions: Ottawa Hospital, University of Ottawa, Massachusetts General Hospital, Dana-Farber Cancer Institute, University of Michigan, Prisma Health, Virginia Oncology Associates, Beth Israel Deaconess Medical Center, Harvard University, Dana-Farber/Harvard Cancer Center, Canadian Cancer Trials Group, Boston Biomedical (United States)
Language: English
Topic: Cancer Cells and Metastasis
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2921875802